Kisho

University of California, San Diego — Rare Disease Pipeline | Kisho

University of California, San Diego

Other

Orphan Designations

0 approved, 1 designated

FDA Approvals

Active Trials

200 recruiting

Rare Diseases

across 26 areas

News (30d)

Quiet

University of California, San Diego is a company with 1 orphan drug designation across 17 rare diseases. Active clinical trials in 21 indications. 11 active policy bills affect their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 14

Designated Only: 3

17 total diseases

Disease	Drug(s)	Stage
Alzheimer disease	-	Des.TrialAppr.
Parkinson disease	-	Des.TrialAppr.
cancer	-	Des.TrialAppr.
cervical cancer	-	Des.TrialAppr.
cervical squamous intraepithelial neoplasia	insecticidal toxin derived from Bacillus thuringiensis	Des.TrialAppr.
childhood malignant neoplasm	-	Des.TrialAppr.
congenital heart disease	-	Des.TrialAppr.
cystic fibrosis	-	Des.TrialAppr.
diabetes mellitus	-	Des.TrialAppr.
epilepsy	-	Des.TrialAppr.
leukodystrophy	-	Des.TrialAppr.
lymphedema	-	Des.TrialAppr.
lymphoma	-	Des.TrialAppr.
microcephaly 7, primary, autosomal recessive	insecticidal toxin derived from Bacillus thuringiensis	Des.TrialAppr.
mitochondrial disease	-	Des.TrialAppr.
podoconiosis	insecticidal toxin derived from Bacillus thuringiensis	Des.TrialAppr.
pulmonary hypertension	-	Des.TrialAppr.